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Summary Although essential thrombocythemia (ET) has been rarely reported
to cause coronary thrombosis, its appropriate management is still undeﬁned. We
describe a case of acute coronary syndrome in a patient with ET. A 47-year-old
woman with ET complained of severe acute chest pain. Primary coronary angiogra-
phy showed severe stenosis with thrombus in the proximal left anterior descendingAnti-platelet drugs;
Hydroxyurea
coronary artery. The patient was treated with anti-platelet drugs and hydroxyurea to
prevent in-stent thrombosis, and subsequently underwent successful coronary angio-
plasty using aspiration and a distal protection device without thrombotic coronary
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bcomplications.
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ssential thrombocythemia (ET), a clonal myelo-
roliferative disorder, increases the risk of both
hrombosis and hemorrhage. Recent studies have
hown that thrombotic complications, especially
hrombus in the cerebral, coronary, and peripheral
rteries, were more frequent than hemorrhage in
atients with ET, and the incidence of acute coro-
ary disease in patients with ET was 9.4% [1].
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Several drugs are presently available for the
revention of thrombus. Aspirin reduces coronary
hrombosis in patients with an elevated platelet
ount and cardiovascular risk factors [2]. Hydrox-
urea is effective for preventing thrombus in
atients with ET who are at high risk for throm-
otic complications. The distal embolization of
therothrombotic material often occurs during per-
utaneous coronary intervention (PCI) in patients
ith thrombotic lesions, and its occurrence is asso-
iated with worse long-term outcomes [3]. The
se of both aspiration thrombectomy and distal
rotection for thrombotic lesions gives excellent
ngiographic results.
gy. Published by Elsevier Ireland Ltd. All rights reserved.
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anterior descending coronary artery. (B) Successful angio
a bare-metal stent without distal embolization.
Since there is as yet no standard treatment
for acute coronary syndrome (ACS) with ET,
we describe successful PCI using both aspiration
thrombectomy and distal protection in combination
with platelet-lowering therapy in a patient with ACS
caused by ET.
Case report
A 47-year-old woman with recently diagnosed ET
was brought to our hospital because of severe
chest and back pain lasting for 30min. She was
diagnosed with ET based on bone marrow histol-
ogy. Her platelet count was 1,295,000/mm3. She
was a smoker and had a past history of hyper-
tension ﬁve years previously, but had no history
of hyperlipidemia, diabetes, or hemorrhagic disor-
h
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Figure 2 (A) The red and white thrombotic materials retrie
wild-type sequence in JAK2. Mutation screening was performcranial). (A) Severe stenosis with thrombus of the left
y using aspiration thrombectomy, distal protection, and
er. The electrocardiogram on admission showed
T depression in leads V3—V6, and the echocar-
iogram showed a slight reduction in wall motion
n the antero-septal region, consistent with ACS.
herefore, anti-platelet therapy with oral aspirin
100mg/day) and clopidogrel (75mg/day) was ini-
iated. Diagnostic coronary angiography revealed
evere stenosis with thrombolysis in myocardial
nfarction (TIMI) grade II in the proximal left
nterior descending (LAD) coronary artery with
hrombus (Fig. 1). However, thrombotic compli-
ations after PCI, such as subacute thrombosis,
ere more likely because of the presence of
T, and thus platelet-lowering therapy using
ydroxyurea (1000mg/day) was initiated. Heparin
10,000U/day) was administered to prevent new
hrombus in addition to oral anti-platelet ther-
py until PCI. Two weeks after the initiation of
ved by Thrombuster III. (B) Sequence traces showing a
ed as described previously [14].
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dFigure 3 Total occlusion of the right brachial arter
ydroxyurea, the platelet count was decreased to
39,000/mm3, and PCI was performed. Thrombec-
omy using an aspiration device (Thrombuster
II, Kaneka Corp., Osaka, Japan) was attempted
ith distal protection (Filtrap, Nipro, Osaka,
apan). The red and white thrombus retrieved by
he Thrombuster III was conﬁrmed (Fig. 2A). A
.0mm× 16mm bare-metal stent (Liberte, Boston
cientiﬁc Japan, Tokyo, Japan) was implanted to
he LAD, resulting in removal of the thrombus with-
ut no reﬂow phenomenon along with successful
ngioplasty. Although six-month follow-up coronary
ngiography revealed no restenosis, late lumen
oss as assessed by quantitative coronary angiogra-
hy was 1.35 [average = 0.69± 0.58 (mean± S.D.),
npublished data]. In addition, total occlusion with
hrombus was seen in the right brachial artery
Fig. 3), and asymmetry of the brachial pulses
nd blood pressure was found. Anticoagulation
herapy with warfarin was started in addition to
nti-platelet therapy and hydroxyurea to prevent
urther thrombotic complications. Since a single
oint mutation (V617F) has frequently been iden-
a
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m
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omonths after percutaneous coronary intervention.
iﬁed in janus kinase 2 (JAK2) in patients with ET
4], we analyzed this mutation, but this patient had
ild-type JAK2 (Fig. 2B).
iscussion
T is a myeloproliferative disorder characterized
y the monoclonal proliferation of hematopoietic
tem cells. ET is manifested clinically by the over-
roduction of platelets in the absence of a deﬁnite
ause and leads to thrombus formation in systemic
rteries including the coronary artery. The overall
ates of thrombosis and hemorrhage at diagnosis
uring follow-up have ranged from 7% to 17% and
% to 14%, respectively [5].
Age, previous thrombotic events, and a long
uration of thrombocytosis have been identiﬁed
s major risk factors for thrombosis in previ-
us reports [6]. Age over 60 and a history of
ajor ischemic events were also risk factors for
therothrombotic complications in a large study
f 148 ET patients [7]. Among cardiovascular risk
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factors, hypertension, hypercholesterolemia, and
smoking were also associated with an increased
risk of developing major vascular complications
in some studies [6]. In this case, a history of
angina, hypertension, and smoking were included
as risk factors for thrombotic events. In addi-
tion to ischemic events, thrombotic occlusion in
the right brachial artery was noted. A previous
study showed that a history of thrombosis at diag-
nosis was signiﬁcantly associated with recurrent
thrombosis [8]. In addition, another thrombotic
event occurred repeatedly despite treatment with
anti-platelet drugs and hydroxyurea. However, we
cannot exclude the possibility that it might be
induced by some injury sustained during the cardiac
catheterization procedure, which was performed
by the right radial artery approach.
Platelet-lowering therapy with hydroxyurea was
started because this case was classiﬁed as high
risk for thrombotic complications. Hydroxyurea has
emerged as the treatment of choice for high-risk
patients with ET because of its efﬁcacy and the
rarity of acute toxicities. A randomized clinical
trial demonstrated that there were signiﬁcantly
fewer thrombotic complications in a hydroxyurea-
treated group than in a control group (1.6% vs
10.7%, p = 0.003) [9]. However, in our patient, a
new thrombotic event occurred in the right brachial
artery despite treatment with hydroxyurea. Corte-
lazzo et al. showed that ET patients with platelet
counts below 600,000/mm3 have a reduced rate
of thrombosis [6]. In this case, platelet counts
decreased from 1,295,000/mm3 to 839,000/mm3
after treatment with hydroxyurea. Our platelet-
lowering therapy with hydroxyurea might have
been inadequate to prevent thrombosis. Consensus-
based practice guidelines for the treatment of
ET have recently been developed in Italy [5].
Young (age <60 years) asymptomatic patients with
platelet counts below 1,500,000/mm3 are at lower
risk for thrombosis and can be followed without
treatment. For high-risk patients (history of throm-
bosis, hemorrhagic complications, platelet count
>1,500,000/mm3, or age >60 years), hydroxyurea
is the treatment of choice because it has been
shown to be effective at preventing thrombotic
complications in a randomized clinical trial. How-
ever, the possible long-term leukemogenicity of
this drug remains a major concern. Anagrelide
and interferon- could overcome this concern and
should be considered for high-risk younger patients.
Our case was a high-risk patient because of a history
of thrombosis, and therefore we chose hydroxyurea
for platelet-lowering therapy.
The combination of aspirin with clopidogrel
and warfarin in addition to hydroxyurea has
p
e
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a
oN. Kumagai et al.
een administered for the prevention of recurrent
hrombosis. De Stefano et al. [10] demonstrated
hat long-term treatments with anti-platelet or
nticoagulant agents were independently effec-
ive for preventing recurrence, with reductions of
e-thrombosis of 58% and 68%, respectively. Fur-
hermore, in a review by Landolﬁ and Di Gennaro
11], they considered that more aggressive anti-
latelet therapy with the combination of aspirin
nd clopidogrel in patients with prior ACS might be
eneﬁcial for preventing re-thrombosis. However,
nti-platelet therapy plus anticoagulants resulted
n a higher incidence of major bleeding (2.8%
atient-years) compared with anti-platelet drug or
nticoagulants alone (0.8% and 0.9% patient-years,
espectively) [10,12]. Careful follow-up would be
eeded to monitor bleeding complications with
ulti anti-thrombotic therapy in this case.
Recently, 4 groups reported that JAK2 V617F
utation could be detected in more than 30%
f patients with ET [13]. Furthermore, the Medi-
al Research Council Primary Thrombocythemia-1
rial studied the effect of JAK2 V617F mutation
n treatment outcome in patients with ET, and
emonstrated that JAK2 V617F mutation-positive
atients were much more sensitive to hydroxyurea
14]. In this case, although we investigated JAK2
617F mutation, this mutation was not identiﬁed.
his may have been associated with the inadequate
ecrease in platelet counts despite treatment with
ydroxyurea.
Intracoronary thrombus remains a challenge for
nterventional catheter-based techniques. Distal
mbolization of thrombus after balloon inﬂation
nd stent implantation carries an increased risk
f a poor clinical outcome [13]. Therefore, dis-
al embolization is considered to be a major
ause of insufﬁcient reperfusion. In this case,
e used both aspiration thrombectomy and dis-
al protection to prevent distal embolization,
nd successful angioplasty was achieved without
omplications.
To our knowledge, there have been 17 reports of
cute myocardial infarction associated with ET in
he literature. In 6 of these patients [15—19], no
rganic stenosis of the coronary artery after stan-
ard therapy for acute myocardial infarction was
ound by coronary angiography. Previous investiga-
ions for the pathogenesis of ACS have shown the
mportance of platelet thrombus formation caused
y vascular endothelial damage resulting from
laque rupture [20]. Considering these cases, how-
ver, thrombus formation due to abnormal platelet
ounts might be the main underlying cause of ACS
ssociated with ET. There have been few reports
n the use of intravascular ultrasound or the his-
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ological examination of coronary artery thrombus
n patients with ACS associated with ET. Therefore,
he characteristics of thrombus and the cause of
cclusion are not precisely known. Further investi-
ation is needed on this point, which could lead to
more appropriate therapy for thrombosis compli-
ating ET.
In conclusion, we performed successful angio-
lasty without distal embolization or coronary
hrombosis after stent implantation in a patient
ith ET. In young patients with ACS, further
valuation for an unusual cause is needed.
dditional therapy, including anti-platelet drugs,
nti-coagulant drugs, and hydroxyurea, should be
tarted when a patient is diagnosed with ET.
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